275 related articles for article (PubMed ID: 22247700)
1. Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt/β-catenin signaling linked to the PDGFR/Src and Rac/PAK pathways.
Zhou L; Ercolano E; Ammoun S; Schmid MC; Barczyk MA; Hanemann CO
Neoplasia; 2011 Dec; 13(12):1101-12. PubMed ID: 22247700
[TBL] [Abstract][Full Text] [Related]
2. Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells.
Petrilli AM; Garcia J; Bott M; Klingeman Plati S; Dinh CT; Bracho OR; Yan D; Zou B; Mittal R; Telischi FF; Liu XZ; Chang LS; Welling DB; Copik AJ; Fernández-Valle C
Oncotarget; 2017 May; 8(19):31666-31681. PubMed ID: 28427224
[TBL] [Abstract][Full Text] [Related]
3. Impaired intercellular adhesion and immature adherens junctions in merlin-deficient human primary schwannoma cells.
Flaiz C; Utermark T; Parkinson DB; Poetsch A; Hanemann CO
Glia; 2008 Apr; 56(5):506-15. PubMed ID: 18240308
[TBL] [Abstract][Full Text] [Related]
4. Merlin, a regulator of Hippo signaling, regulates Wnt/β-catenin signaling.
Kim S; Jho EH
BMB Rep; 2016 Jul; 49(7):357-8. PubMed ID: 27345717
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells.
Kaempchen K; Mielke K; Utermark T; Langmesser S; Hanemann CO
Hum Mol Genet; 2003 Jun; 12(11):1211-21. PubMed ID: 12761036
[TBL] [Abstract][Full Text] [Related]
6. The role of insulin-like growth factors signaling in merlin-deficient human schwannomas.
Ammoun S; Schmid MC; Ristic N; Zhou L; Hilton D; Ercolano E; Carroll C; Hanemann CO
Glia; 2012 Nov; 60(11):1721-33. PubMed ID: 22821509
[TBL] [Abstract][Full Text] [Related]
7. Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2.
Ammoun S; Schmid MC; Triner J; Manley P; Hanemann CO
Neuro Oncol; 2011 Jul; 13(7):759-66. PubMed ID: 21727212
[TBL] [Abstract][Full Text] [Related]
8. The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours.
Ammoun S; Schmid MC; Zhou L; Hilton DA; Barczyk M; Hanemann CO
Mol Oncol; 2015 Jan; 9(1):236-48. PubMed ID: 25217104
[TBL] [Abstract][Full Text] [Related]
9. Merlin inhibits Wnt/β-catenin signaling by blocking LRP6 phosphorylation.
Kim M; Kim S; Lee SH; Kim W; Sohn MJ; Kim HS; Kim J; Jho EH
Cell Death Differ; 2016 Oct; 23(10):1638-47. PubMed ID: 27285107
[TBL] [Abstract][Full Text] [Related]
10. Altered adhesive structures and their relation to RhoGTPase activation in merlin-deficient Schwannoma.
Flaiz C; Ammoun S; Biebl A; Hanemann CO
Brain Pathol; 2009 Jan; 19(1):27-38. PubMed ID: 18445079
[TBL] [Abstract][Full Text] [Related]
11. NF2-deficient cells depend on the Rac1-canonical Wnt signaling pathway to promote the loss of contact inhibition of proliferation.
Bosco EE; Nakai Y; Hennigan RF; Ratner N; Zheng Y
Oncogene; 2010 Apr; 29(17):2540-9. PubMed ID: 20154721
[TBL] [Abstract][Full Text] [Related]
12. The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors.
Zhou L; Lyons-Rimmer J; Ammoun S; Müller J; Lasonder E; Sharma V; Ercolano E; Hilton D; Taiwo I; Barczyk M; Hanemann CO
Oncogene; 2016 Jun; 35(26):3443-53. PubMed ID: 26549023
[TBL] [Abstract][Full Text] [Related]
13. Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival.
Ammoun S; Provenzano L; Zhou L; Barczyk M; Evans K; Hilton DA; Hafizi S; Hanemann CO
Oncogene; 2014 Jan; 33(3):336-46. PubMed ID: 23318455
[TBL] [Abstract][Full Text] [Related]
14. Loss of tumor suppressor Merlin results in aberrant activation of Wnt/β-catenin signaling in cancer.
Morrow KA; Das S; Meng E; Menezes ME; Bailey SK; Metge BJ; Buchsbaum DJ; Samant RS; Shevde LA
Oncotarget; 2016 Apr; 7(14):17991-8005. PubMed ID: 26908451
[TBL] [Abstract][Full Text] [Related]
15. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.
James MF; Han S; Polizzano C; Plotkin SR; Manning BD; Stemmer-Rachamimov AO; Gusella JF; Ramesh V
Mol Cell Biol; 2009 Aug; 29(15):4250-61. PubMed ID: 19451225
[TBL] [Abstract][Full Text] [Related]
16. Merlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane.
Okada T; Lopez-Lago M; Giancotti FG
J Cell Biol; 2005 Oct; 171(2):361-71. PubMed ID: 16247032
[TBL] [Abstract][Full Text] [Related]
17. Emerging therapeutic targets in schwannomas and other merlin-deficient tumors.
Ammoun S; Hanemann CO
Nat Rev Neurol; 2011 Jun; 7(7):392-9. PubMed ID: 21647202
[TBL] [Abstract][Full Text] [Related]
18. The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression.
Xiao GH; Gallagher R; Shetler J; Skele K; Altomare DA; Pestell RG; Jhanwar S; Testa JR
Mol Cell Biol; 2005 Mar; 25(6):2384-94. PubMed ID: 15743831
[TBL] [Abstract][Full Text] [Related]
19. NF2/Merlin is required for the axial pattern formation in the Xenopus laevis embryo.
Zhu X; Min Z; Tan R; Tao Q
Mech Dev; 2015 Nov; 138 Pt 3():305-12. PubMed ID: 26344136
[TBL] [Abstract][Full Text] [Related]
20. Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma.
Ammoun S; Flaiz C; Ristic N; Schuldt J; Hanemann CO
Cancer Res; 2008 Jul; 68(13):5236-45. PubMed ID: 18593924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
